Endo to buy Indevus for $370M up front, to expand portfolio beyond pain management
Endo Pharmaceuticals has agreed to buy fellow US firm Indevus Pharmaceuticals for as much as $637.0 million, in a deal that will add 100 representatives to its sales force and expand its portfolio beyond pain management.
Endo will initially pay $4.50 a share, or about $370.0 million in total, for the Lexington, Massachusetts-based firm whose products include treatments for overactive bladder, prostate cancer and central precocious puberty, with drugs for hypogonadism and bladder cancer nearing approval. The initial price offered is 45% above Indevus' $3.10 closing price at 4pm New York on the day the deal was announced, January 5.
Under the terms of the deal, Endo will pay an additional $3 per share, valued at an extra $267.0 million, if Indevus meets certain regulatory and sales milestones.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze